Answers are grounded in this paper and cite their sources.
PIV is a strong predictor of survival outcomes with better performance than other well-known IIBs in patients with mCRC treated with first-line therapy. PIV should be prospectively validated to better stratify mCRC patients undergoing first-line therapy.
No takes yet. Share an insight, caveat, or question.
Fucà et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: